nitric oxide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
== Overdose == In high doses, overdoses, or in some persons not tolerant to opioids, oxycodone can cause shallow breathing, slowed heart rate, cold/clammy skin, pauses in breathing, low blood pressure, constricted pupils, circulatory collapse, respiratory arrest, and death. In 2011, it was the leading cause of drug-related deaths in the U.S. However, from 2012 onwards, heroin and fentanyl have become more common causes of drug-related deaths.
== Deaths == 1 January – Sally Oppenheim-Barnes, Baroness Oppenheim-Barnes, 96, British politician, minister of state for consumer affairs (1979–1982), MP (1970–1987), and member of the House of Lords (1989–2019). 4 January – Jenny Randerson, Baroness Randerson, 76, Welsh politician and peer, acting Deputy First Minister of Wales (2001–2002) and member of the House of Lords (since 2011). 24 January – Joan Hanham, Baroness Hanham, 85, British politician, member of the House of Lords (1999–2020) and leader of the Kensington and Chelsea Council (1989–2000). 1 February – John Montagu, 11th Earl of Sandwich, 81, British aristocrat, businessman and politician, member of the House of Lords (1995–2024). 7 February – Dafydd Elis-Thomas, Baron Elis-Thomas, 78, Welsh politician, llywydd of the Senedd (1999–2011), MP (1974–1992) and member of the House of Lords (since 1992). 16 February – Barry Panter, politician (Mayor of Newcastle-under-Lyme), car crash. (death reported on this date) 19 February – Joe Haines, 97, British journalist and public servant, Downing Street press secretary (1969–1970, 1974–1976). 27 March – Christina McKelvie, 57, Scottish politician, MSP (since 2007), minister for culture (2023–2024) and drugs and alcohol policy (since 2024), breast cancer. 30 March – Stanley Kalms, Baron Kalms, 93, British businessman, chairman of Currys, and life peer, member of the House of Lords (2004–2024). 31 March – Janric Craig, 3rd Viscount Craigavon, 80, British hereditary peer and member of the House of Lords (since 1974) 23 April – Peter Taaffe, 83, British Marxist militant.
=== Plants === Carnivorous plants can survive without eating prey. Catching insects, however, supports their growth. Mushrooms, molds, and other fungi are not plants, despite similarities in their morphology and lifestyle. The historical classification of fungi as plants is defunct, and although they are still commonly included in botany curricula and textbooks, modern molecular evidence shows that fungi are more closely related to animals than to plants. Poinsettias are not highly toxic to humans or cats. While it is true that they are mildly irritating to the skin or stomach, and may sometimes cause diarrhea and vomiting if eaten, they rarely cause serious medical problems. Sunflowers do not always point to the Sun. Flowering sunflowers face a fixed direction (often east) all day long, but do not necessarily face the Sun. However, in an earlier developmental stage, before the appearance of flower heads, the immature buds do track the Sun (a phenomenon called heliotropism).
Mylodontidae is a family of extinct South American and North American ground sloths within the suborder Folivora of order Pilosa, living from around 23 million years ago (Mya) to 11,000 years ago. This family is most closely related to another family of extinct ground sloths, Scelidotheriidae, as well as to the extant arboreal two-toed sloths, family Choloepodidae; together these make up the superfamily Mylodontoidea. Phylogenetic analyses based on morphology uncovered the relationship between Mylodontidae and Scelidotheriidae; in fact, the latter was for a time considered a subfamily of mylodontids. However, molecular sequence comparisons were needed for the correct placement of Choloepodidae. These studies have been carried out using mitochondrial DNA sequences as well as with collagen amino acid sequences. The latter results indicate that Choloepodidae is closer to Mylodontidae than Scelidotheriidae is. The only other living sloth family, Bradypodidae (three-toed sloths), belongs to a different sloth radiation, Megatherioidea. The mylodontoids form one of three major radiations of sloths. The discovery of their fossils in caverns associated with human occupation lead some early researchers to theorize that the early humans built corrals when they could procure a young ground sloth, to raise the animal to butchering size. However, radiocarbon dates do not support simultaneous occupation of the site by humans and sloths. Subfossil remains like coproliths, fur and skin have been discovered in some quantities.
Sources: en.wikipedia.org
Powys covers the historic counties of Montgomeryshire and Radnorshire, most of Brecknockshire, and part of historic Denbighshire. With an area of about 2,000 square miles (5,200 km2), it is now the largest administrative area in Wales by land and area (Dyfed was until 1996 before several former counties created by the Local Government Act 1972 were abolished). It is bounded to the north by Gwynedd, Denbighshire and Wrexham County Borough; to the west by Ceredigion and Carmarthenshire; to the east by Shropshire and Herefordshire; and to the south by Rhondda Cynon Taf, Merthyr Tydfil County Borough, Caerphilly County Borough, Blaenau Gwent, Monmouthshire and Neath Port Talbot. The largest towns are Newtown, Ystradgynlais, Brecon, Welshpool, Llandrindod Wells and Knighton. Powys has the lowest population density of all the principal areas of Wales. Most of Powys is mountainous, and most roads and railways are relatively slow. Just under a third of the residents have Welsh linguistic skills: Welsh speakers are concentrated mainly in the rural areas both in and around Machynlleth, Llanfyllin and Llanrhaeadr-ym-Mochnant (where William Morgan first translated the whole Bible into Welsh in 1588) in Montgomeryshire, and the industrial area of Ystradgynlais in the southwest of Brecknockshire. In Radnorshire, the language survived into the 20th century west of Rhayader with a few native speakers from Nantmel parish surviving into the 20th century too.
They finally arrived at Funchal on 19 November. Their children were being looked after at Wartegg Castle in Switzerland by Charles's step-grandmother Maria Theresa, although Zita managed to see them in Zürich when her son Robert needed an operation for appendicitis. The children joined their parents in Madeira in February 1922.
== Definition == Vitamin A is a fat-soluble vitamin, a category that also includes vitamins D, E and K. The vitamin encompasses several chemically related naturally occurring compounds or metabolites, i.e., vitamers, that all contain a β-ionone ring. The primary dietary form is retinol, which may have a fatty acid molecule attached, creating a retinyl ester, when stored in the liver. Retinol – the transport and storage form of vitamin A – is interconvertible with retinal, catalyzed to retinal by retinol dehydrogenases and back to retinol by retinaldehyde reductases.
Sources: en.wikipedia.org
==== Due to use of medication ==== Urine tests can be falsely positive in those that are taking the medications: chlorpromazine, promethazine, phenothiazines, methadone, aspirin, carbamazepine and drugs that cause high urinary pH.
Antiviral drugs are a class of medication used specifically for treating viral infections. Like antibiotics, specific antivirals are used for specific viruses. They should be distinguished from viricides, which actively deactivate virus particles outside the body. Many antiviral drugs are designed to treat infections by retroviruses, including HIV. Important antiretroviral drugs include the class of protease inhibitors. Herpes viruses, best known for causing cold sores and genital herpes, are usually treated with the nucleoside analogue acyclovir. Viral hepatitis is caused by five unrelated hepatotropic viruses (A-E) and may be treated with antiviral drugs depending on the type of infection. Some influenza A and B viruses have become resistant to neuraminidase inhibitors such as oseltamivir, and the search for new substances continues.
Many bird species migrate to take advantage of global differences of seasonal temperatures, therefore optimising availability of food sources and breeding habitat. These migrations vary among the different groups. Many landbirds, shorebirds, and waterbirds undertake annual long-distance migrations, usually triggered by the length of daylight as well as weather conditions. These birds are characterised by a breeding season spent in the temperate or polar regions and a non-breeding season in the tropical regions or opposite hemisphere. Before migration, birds substantially increase body fats and reserves and reduce the size of some of their organs. Migration is highly demanding energetically, particularly as birds need to cross deserts and oceans without refuelling. Landbirds have a flight range of around 2,500 km (1,600 mi) and shorebirds can fly up to 4,000 km (2,500 mi), although the bar-tailed godwit is capable of non-stop flights of up to 10,200 km (6,300 mi). Some seabirds undertake long migrations, with the longest annual migrations including those of Arctic terns, which were recorded travelling an average of 70,900 km (44,100 mi) between their Arctic breeding grounds in Greenland and Iceland and their wintering grounds in Antarctica, with one bird covering 81,600 km (50,700 mi), and sooty shearwaters, which nest in New Zealand and Chile and make annual round trips of 64,000 km (39,800 mi) to their summer feeding grounds in the North Pacific off Japan, Alaska and California. Other seabirds disperse after breeding, travelling widely but having no set migration route.
== Expression of Draculin == As a naturally occurring anticoagulant, research into Draculin promises therapeutic strategy into new anticoagulants and provides a foundation for deeper investigations into FXa related coagulation mechanisms. Since the first step of the Draculin-FXa mechanism is driven by concentration and the second step is concentration independent, the FXa-Draculin complex behaves as irreversible under experimental conditions. Glycosylation is a common post-translational modification in which carbohydrates (glycans) are added to proteins or lipids. The resulting glycoproteins and glycolipids acquire altered physical and biochemical properties. As a glycoprotein, Draculin requires a specific glycosylation profile to express its maximum inhibitory activity. Its attached oligosaccharides are essential FXa inhibition, as demonstrated by the loss of anti-Xa activity following incubation with the lectins WGA and PNA.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.